Arformoterol Tartrate Solution
Product Images NDC 70756-612

The text describes a figure (Figure 1) showing a comparison of mean change in FEV (Forced Expiratory Volume) from baseline between two groups over Hours Postdose. One group received placebo (n=143) and had a baseline FEV1 of 1.20 L, while the other group received 15 mcg Arformoterol Tartrate inhalation solution BID (n=141) and had a baseline FEV1 of 1.15 L.*

This text describes a figure showing the mean change in Forced Expiratory Volume in 1 second (FEV1) over time for Clinical Trial A at Week 12. The figure shows the changes in FEV1 in Liters (L) for a placebo group (n=143) and a group given Arformoterol Tartrate Inhalation Solution BID (n=141) at baseline FEV1 levels of 1.20 L and 1.15 L, respectively. The data is plotted against hours postdose and the mean change in FEV1 is noted for different time intervals.*

This is an inhalation solution that is contained in a 2 mL sterile unit-dose vial for Rx use only. The temperature storage and use by date are not available. The solution contains arformoterol tartrate expressed as 15 mcg/2 mL potency, and it should be opened just prior to administration. The text also warns to keep the solution out of children's reach. The rest of the text seems to be not available as it contains non-English characters and errors.*

Arformoterol Tartrate Inhalation Solution is a bronchodilator medication used for the treatment of breathing problems in patients suffering from chronic obstructive pulmonary disease (COPD). The solution comes in a carton of sixty 2 mL unit-dose vials that need to be refrigerated or stored at room temperature. Each 2 mL unit-dose vial contains 15 μg of arformoterol tartrate inhalation solution, equivalent to 22 μg of arformoterol tartrate in 3 mL of sodium chloride solution. The medication is only available with a prescription, and the proper dosage must be determined by a qualified physician. The package comes with a warning label and should be kept out of children's reach.*